177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
Journal of Nuclear Medicine · 2025-02 · 66 (2) · 238-244
DOI: 10.2967/jnumed.124.268617 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.01.2025. Verfasst von Swayamjeet Satapathy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Capecitabine, Neuroendocrine Tumors, Organometallic Compounds, Octreotide. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India; sood99@yahoo.com.
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
- Department of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Montefiore Medical Center, Bronx, New York.
- Department of GI Surgery, HPB and Liver Transplantation, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Satapathy, S., Aggarwal, P., Sood, A., Chandekar, K. R., Das, C. K., Gupta, R., Khosla, D., Das, N., Kapoor, R., Kumar, R., Singh, H., Shukla, J., Kumar, A., & Mittal, B. R. (2025). 177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. Journal of Nuclear Medicine, 66(2), 238-244. https://doi.org/10.2967/jnumed.124.268617
Vancouver
Satapathy S, Aggarwal P, Sood A, Chandekar KR, Das CK, Gupta R, et al. 177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. Journal of Nuclear Medicine. 2025;66(2):238-244. doi:10.2967/jnumed.124.268617
BibTeX
@article{Satapathy2025,
author = {Satapathy, Swayamjeet and Aggarwal, Piyush and Sood, Ashwani and Chandekar, Kunal R and Das, Chandan K and Gupta, Rajesh and Khosla, Divya and Das, Namrata and Kapoor, Rakesh and Kumar, Rajender and Singh, Harmandeep and Shukla, Jaya and Kumar, Ajay and Mittal, Bhagwant Rai},
title = {177 Lu-DOTATATE Plus Capecitabine Versus 177 Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {2},
pages = {238--244},
doi = {10.2967/jnumed.124.268617}
}
EUVIMED